(Q33409192)

English

Short duration, high dose, alternating chemotherapy in metastatic neuroblastoma. (ENSG 3C induction regimen). The European Neuroblastoma Study Group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Short duration, high dose, alternating chemotherapy in metastatic neuroblastoma. (ENSG 3C induction regimen). The European Neuroblastoma Study Group (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Pinkerton CR

1

1 reference

Europe PubMed Central

26 July 2017

Zucker JM

2

1 reference

Europe PubMed Central

26 July 2017

Hartmann O

3

1 reference

Europe PubMed Central

26 July 2017

Pritchard J

4

1 reference

Europe PubMed Central

26 July 2017

Broadbent V

5

1 reference

Europe PubMed Central

26 July 2017

Morris-Jones P

6

1 reference

Europe PubMed Central

26 July 2017

Breatnach F

7

1 reference

Europe PubMed Central

26 July 2017

Craft AE

8

1 reference

Europe PubMed Central

26 July 2017

Pearson AD

9

1 reference

Europe PubMed Central

26 July 2017

Wallendszus KR

10

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

1 August 1990

1 reference

Europe PubMed Central

26 July 2017

British Journal of Cancer

1 reference

Europe PubMed Central

26 July 2017

62

1 reference

Europe PubMed Central

26 July 2017

2

1 reference

Europe PubMed Central

26 July 2017

319-323

1 reference

Europe PubMed Central

26 July 2017

https://scigraph.springernature.com/pub.10.1038/bjc.1990.286

0 references

Chemotherapy of advanced neuroblastoma: does adriamycin contribute?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971805

28 July 2018

Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: response and toxicity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971805

28 July 2018

A phase II study of ifosfamide in children with recurrent solid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971805

28 July 2018

Sequential cisplatin/VM-26 and vincristine/cyclophosphamide/doxorubicin in metastatic neuroblastoma: an effective alternating non-cross-resistant regimen?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971805

28 July 2018

A phase II study of high-dose cisplatin and VP-16 in neuroblastoma: a report from the Société Française d'Oncologie Pédiatrique

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971805

28 July 2018

Very-high-dose cisplatin and etoposide in children with untreated advanced neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971805

28 July 2018

Coordinated use of sequentially escalated cyclophosphamide and cell-cycle-specific chemotherapy (N4SE protocol) for advanced neuroblastoma: experience with 100 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971805

28 July 2018

Ototoxicity of high-dose cis-platinum in children.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971805

28 July 2018

Multiagent chemotherapy for children with metastatic neuroblastoma: a report from Childrens Cancer Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971805

28 July 2018

VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971805

28 July 2018

Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971805

31 October 2018

Single-agent ifosfamide in patients with recurrent neuroblastoma (ENSG study 2). European Neuroblastoma Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/2386751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intensive chemotherapy for metastatic neuroblastoma: a Southwest Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/2386751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuroblastoma: the Joint Center for Radiation Therapy/Dana-Farber Cancer Institute/Children's Hospital experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/2386751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose chemoradiotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: an unselected group of stage IV patients over 1 year of age

1 reference

https://pubmed.ncbi.nlm.nih.gov/2386751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/2386751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Specificity of iodobenzylguanidine scanning in neuroblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/2386751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ifosfamide in previously untreated disseminated neuroblastoma. Results of Study 3A of the European Neuroblastoma Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/2386751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1990.286

1 reference

Europe PubMed Central

26 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33409192&oldid=1644826296"